Supportive Medicines - additional products (ITU, Antibiotics & EOI medicines)
A procurement exercise for supportive medicines that includes End of Life, Intensive Treatment Unit and Antibiotics medicines.
Buyer
Department of Health and Social Care (DHSC)
Value
£32,590,176
Published
30 Apr 2021
Closes
1 Nov 2020
Procurement details
Source
Contracts Finder
Region
United Kingdom
Procurement method
Open
Category
Goods
Contract starts
1 Dec 2020
Contract ends
1 Dec 2020
CPV classifications
33600000
Pharmaceutical products
Lots
Lot default Supportive Medicines - additional products (ITU, Antibiotics & EOI medicines)
£16,295,088
A procurement exercise for supportive medicines that includes End of Life, Intensive Treatment Unit and Antibiotics medicines.
Delivery: United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
16 Apr 2021
Awarded contract notice on Contracts Finder
Award notice · Web page
CST_Doc.3a_Conditions_of_Contract_Licensed_Medicines_CM_EMI_20_12107_REDACTED
Not provided
CST_Doc.3a_Conditions_of_Contract_Licensed_Medicines_CM_EMI_20_12107_REDACTED
Link
Kent _Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107 REDACTED
Not provided
Kent _Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107 REDACTED
Link
Mercury_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107 REDACTED
Not provided
Mercury_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107 REDACTED
Link
Accord_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107_REDACTED
Not provided
Accord_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107_REDACTED
Link
Wockhardt_Doc.3a_Conditions_of_Contract_Licensed_Medicines_CM_EMI_20_12107 REDACTED
Not provided
Wockhardt_Doc.3a_Conditions_of_Contract_Licensed_Medicines_CM_EMI_20_12107 REDACTED
Link
Aguettant_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107_REDACTED
Not provided
Aguettant_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107_REDACTED
Link
aspen_Doc.3a_Conditions_of_Contract_Licensed_Medicines_CM_EMI_20_12107_REDACTED
Not provided
aspen_Doc.3a_Conditions_of_Contract_Licensed_Medicines_CM_EMI_20_12107_REDACTED
Link
BioQ_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107_REDACTED
Not provided
BioQ_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107_REDACTED
Link
Hameln_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107 REVISED REDACTED
Not provided
Hameln_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107 REVISED REDACTED
Link
Aventis Pharma_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107_REDACTED
Not provided
Aventis Pharma_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107_REDACTED
Link
BBraun_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107_REDACTED
Not provided
BBraun_Doc3a_Conditions of Contract_Licensed Medicines_CM_EMI_20_12107_REDACTED
Link
Contains public sector information licensed under the Open Government Licence v3.0.